+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Exacerbation of Wegener’s Granulomatosis following Single Administration of Monoclonal Antibody 17-1A (Panorex ®) during Adjuvant Immunotherapy of Colon Cancer

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background: Immunotherapy with monoclonal antibody 17-1A (mAb 17-1A) has been shown effective as an adjuvant treatment in UICC stage III colon carcinoma. Usually, severe side effects are infrequent with mAb 17-1A treatment. Case Report: A 64-year-old man had a 18-month history of recurring arthralgia, sinusitis, and conjunctivits. After curative resection of UICC stage II colon cancer adjuvant treatment with mAb 17-1A was initiated. After the first administration (500 mg) the patient experienced an aggravation of the above-mentioned symptoms which led to the diagnosis of Wegener’s granulomatosis with multiorgan involvement. Under immunosuppressive therapy with cyclophosphamide and prednisone, clinical stabilization could be achieved. Conclusion: The exacerbation of Wegener’s granulomatosis occurred immediately after the first administration of mAb 17-1A. This suggests that mAb 17-1A should be applied cautiously in autoimmune disease.

          Related collections

          Author and article information

          Oncol Res Treat
          Oncology Research and Treatment
          S. Karger AG
          October 2000
          03 November 2000
          : 23
          : 5
          : 472-474
          aOnkologisches Zentrum, III. Medizinische Klinik, Universitätsklinikum Mannheim, aOstalbklinikum Aalen
          27216 Onkologie 2000;23:472–474
          © 2000 S. Karger GmbH, Freiburg

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 3
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/27216
          Casuistic Contribution · Kasuistik


          Comment on this article